Acquisition of VIDAL Group by M3.
VIDAL Group, a drug information specialist, announces a draft agreement providing for the acquisition of the entire group by the Japanese company M3 for approximately €100 million. This draft agreement is expected to be finalized by the end of 2016. M3 is a leader in the medical information and new technologies sector in Japan, the US and worldwide. A leader in the field of healthcare product databases, VIDAL Group has led a complete transition to digital in recent years to become a key player in medical information in France and Europe.